Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05443633
Other study ID # STUDY00001134
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2022
Est. completion date December 15, 2028

Study information

Verified date September 2023
Source University of Arizona
Contact Aneta Kielar, PhD
Phone 15204883791
Email akielar@email.arizona.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.


Description:

The purpose of this study is to develop semantic-based treatment to address language deficits in individuals with acquired language disorders. We propose to develop an individually optimized semantic-based protocol for strategy implementation and word finding facilitation among individuals with language disorders. Phase 1: Following screening, participants who fulfill the inclusion criteria and have consented to participate in the study will undergo baseline cognitive and language assessment, electroencephalography (EEG) recording and the magnetic resonance imaging (MRI) scan. Participants with language disorders will proceed to the following phases. Phase 2: After baseline assessment, participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks. Phase 3: Directly following treatment, patients will undergo cognitive and language assessment, EEG recording, and an MRI scan. This is done to test for short-term changes in behavioral abilities and neural patterns. Phase 4: After 2 months after the treatment, participants will undergo cognitive and language assessment, EEG recording, and an MRI scan. This final phase of testing is done to test for long-term changes in behavioral abilities and neural responses.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 15, 2028
Est. primary completion date June 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: 1. Present with speech-language impairment (aphasia) caused by stroke or dementia 2. A medical diagnosis of primary progressive aphasia (PPA) by a neurologist or physician 3. Are native speakers of English 4. Present with no contraindications for MRI 5. Have adequate (normal or corrected to normal) vision and hearing Exclusion Criteria: 1. Individuals diagnosed with mood, anxiety, psychotic or substance abuse disorders. 2. Individuals with highly magnetizable metallic implants, including certain dental work, may be excluded due to image quality in MRI. 3. Individuals with other neurological disorders besides the ones of interest for the study (e.g., epilepsy, Multiple Sclerosis, Parkinson's Disease) 4. Individuals with contraindications for MRI. This includes but is not limited to pacemakers, metallic cardiac pumps, valves, magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field. 5. Individuals suffering from clinically significant claustrophobia 6. Severe systemic disease (e.g., renal failure) 7. Poor overall health 8. Individuals who are pregnant 9. Individuals with a history of epileptic activity in the past 12 months 10. Individuals with a personal or family history of epilepsy or other seizure disorders will not be included in the study. 11. Individuals who have had a brain surgery in the past 12. Individuals with implanted metallic skull plates or intracranial implants 13. Individuals with skin lesions or skull damage 14. Individuals who have a history of excessive use of alcohol or drugs 15. Individuals with premorbid psychiatric disease affecting communication 16. Individuals with severe non-linguistic cognitive disturbances impeding language therapy

Study Design


Intervention

Behavioral:
individualized speech-language training
Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
standard language intervention
Participants will undergo standard speech-language naming therapy

Locations

Country Name City State
United States University of Arizona Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change from baseline scores on the naming task Mean change from baseline scores on the Boston Naming Test: Min score = 0; Max = 60; higher scores indicate better outcome through study completion, an average of 1 year
Primary Mean change from baseline scores in aphasia severity Mean change from baseline scores on the Western Aphasia Battery: Min score = 0; Max = 100; higher scores indicate better outcome through study completion, an average of 1 year
Primary Mean change from baseline scores on the language probe task before and after each session change on on the probe task from before the session; Min =0; Max = 100%; higher scores indicate better outcome through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT04957537 - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia N/A
Completed NCT04045990 - Network Modulation in Alzheimer's Disease N/A
Completed NCT05860647 - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia N/A
Recruiting NCT03887481 - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA N/A
Completed NCT03728582 - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Completed NCT02541097 - Preventing Language Decline in Dementia N/A
Recruiting NCT00537004 - Language in Primary Progressive Aphasia
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Active, not recruiting NCT05742698 - Nabilone for Agitation in Frontotemporal Dementia Phase 2
Completed NCT02439853 - Communication Bridge Speech Therapy Research Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Completed NCT04726527 - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Completed NCT05537688 - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed NCT05525377 - Better Living With Non-memory-led Dementia N/A
Not yet recruiting NCT06191198 - Communication Bridge 3 Study Phase 2
Completed NCT02928848 - Transcranial Direct Current Stimulation for Primary Progressive Aphasia N/A
Completed NCT04939818 - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders